EU pharmacovigilance fee proposal trumps agency remuneration puzzle
This article was originally published in Scrip
It looks as if the European Medicines Agency will have to wait for a while yet before it can turn its full attention to the thorny question of how national agencies should be remunerated for their work on behalf of the EU drug regulatory system.
You may also be interested in...
AstraZeneca’s Lynparza can now be used on the Scottish National Health Service for newly diagnosed advanced ovarian cancer.
As stockpiles of Ebola vaccine are being built up around the world, Médecins sans Frontières has said more action is needed to ensure sufficient numbers of vaccinations are available for use in current and future outbreaks.
The new EU commissioner for health has been given a number of high-priority tasks, including medicines supply and tackling antimicrobial resistance. These topics will be taken up by the European Commission’s advisory body, the Pharmaceutical Committee, in its new work plan.